secwatch.observer — SEC 8-K summary
======================================

Issuer:     STRATA Skin Sciences, Inc. (SSKN)
CIK:        0001051514
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001140361-23-038802
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

STRATA Skin Sciences Q2 revenue $8.3M, net loss $3.1M; FY guidance cut to $35-38M
--------------------------------------------------------------------------------

- Q2 revenue $8.3M vs $9.1M YoY; equipment revenue down to $2.8M from $3.5M due to $1.5M one-time China sale last year.
- Net loss $3.1M ($0.09 loss per share) vs $1.9M ($0.05 loss) YoY; adjusted EBITDA loss of $95K vs positive $207K.
- FY 2023 guidance revised to $35-38M from prior; cites slowdown in capex and macro factors impacting equipment sales.
- Secured up to $12M financing with MidCap Financial; cash balance $10.4M; includes refinancing and $7M new tranche.
- 73 TheraClear X devices placed; initiated acne clinical study; JCAD publication released.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1051514/000114036123038802/0001140361-23-038802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1051514/000114036123038802/brhc20057162_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-038802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer